Microcrystalline Cellulose, a Direct Compression Binder in a Quality by Design Environment—A Review
Microcrystalline Cellulose, a Direct Compression Binder in a QbD
July 30, 2018
Impact of Porosity of on Drug Dissolution
The Impact of Porosity of Modified Excipient on Drug Dissolution
August 18, 2018
Show all

How Excipients Affect Drug Quality in Pharmaceutical Industry

Excipients Affect Drug Quality in Pharmaceutical Industry

Pharmaceutical industry has been continually stressing on product quality, adequacy, and wellbeing. Presently, the procedure computerization is considered to be heading Pharmaceutical Industry.

As nowadays, these quality, wellbeing, and viability of the items are the prime necessities. Subsequently, the regulatory bodies are concentrating on executing quality by design (QbD) which is the science-based approach for better product and process understanding by lessening process variety and the empowering process-control procedures.

Key Elements of QbD

  • Quality Target Product Profile: It encompasses the quality characteristics like sterility, purity, shelf life etc.
  • Critical Quality Attribute (CQA): These are the attributes when administered within a particular limit or range offers a desired quality of the product. CQA’s are extracted from the QTTP. The list of CQA can be dynamic and can be updated on the product and process information.
  • Critical Process Parameter (CPP): These are the parameters that have a crucial influence on the CQA when they are changed. Therefore, it is essential to control them to achieve the desired product quality and process consistency. Parameters can be mixing speed, flow rate etc.
  • Critical Material Attribute (CMA): Material attributes are particle size, moisture etc.
  • Design Space: It is a combination and interaction of material attributes and process attributes to provide quality assurance.
  • Design of experiments (DOE): DOE is used for new product and process development. It enhances the robustness testing of products and processes. It screens some important factors and optimizes the quality performance of a product.
  • Operating Space or Range
  • Pharmaceutical Excipients: Excipients are the important ingredient of any formulation. Excipient quality influences the products. Pharma companies need to understand the excipient variability in the raw material and manufacturing process. QbD is a very broad concept and the principles are applied in design space to facilitate understanding of excipient functionality.

How the Properties of an Excipient May Affect Drug Product Performance

The quality, performance or processing of final drug product are affected by physiological and mechanical properties of an excipient. Properties of excipient exhibits variability, because of the variation of raw material and manufacturing process. The source of an excipient can be natural, semi natural, synthetic or semi synthetic. Example of natural excipient is Microcrystalline Cellulose; it is derived from wood pulp. Due to natural source variation, many a times batch blending is required to meet product specification. Croscarmellose sodium is a cross linked polymer of carboxy methyl cellulose sodium. Generally, natural excipient show higher variability as compared to synthetic excipient. Excipients with high variability can be harmful when it affects the potency, purity of a drug product. It also affects the performance and quality of delivery systems such as Modified Release (MR). The quality of excipient may vary from supplier to supplier and even batch to batch.

A Solution for Handling Variability

Not all excipients or all properties are basic to product quality and execution. Each medication item and related assembling process is novel and impacted by individual excipients to an alternate degree. Consequently, a hazard and science-based approach is required to oversee and address excipient fluctuation.

For some, excipients, proper tests and particulars are set up to guarantee predictable quality and solid execution at a satisfactory hazard level related with the general end-utilize applications. For excipient properties that are basic to quality traits of medication products, particularly more refined items (e.g., MR and ASD) with more elevated amount of hazard and effect, a more top to bottom comprehension is required by nearly linking excipient credits to the expected capacity and by deciding how excipient usefulness can be controlled and whether extra item particular determinations ought to be included based detailing and process understanding.

For instance, understanding excipient’s basic part in product or reactivity between the impurities influences with a particular API can help give an answer custom-made to an especially delicate API.

To build up a vigorous definition as well as process that are equipped for enduring excipient inconstancy, pharma organizations and excipient providers need to nearly team up and trade data. Pharma organizations need to share subtle elements on the end-utilize utilization of the excipient, required usefulness and characteristics, and issues experienced or foreseen at the beginning time of improvement.

The excipient makers need to share their insight and skill to help assess excipient properties basic to the medication item by giving inside and out portrayal and recorded information and distinguishing crude material and assembling factors or changes that can conceivably influence these properties and usefulness. This kind of collaboration can help build up a compelling and pragmatic way to deal with foresee and control future cluster to-group fluctuation inside worthy reaches.

To conclude, to control, diminish or limit the conceivable negative effect of excipient variability on products and procedure, a collective effort among pharma organizations, excipient manufacturing companies are required.